Otenabant hydrochloride

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameOtenabant hydrochloride
Drug Alias Nameotenabant奥太纳班otenabantum奥特纳班奥替那班 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor antagonists
TargetsCannabinoid CB1 receptor
Therapy Area/IndicationsObesityHepatic InsufficiencyMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[18] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncNational Institute On Aging (NIA)
Active IndicationsN/A
Inactive IndicationsObesityHepatic InsufficiencyMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG